Dr. Gaston De Serres is an epidemiologist practitioner at the l’Institut national de santé publique du Québec and a regular researcher in the Infectious and Immune Disease Axis at the CHU de Québec-Laval University. He is a full professor in epidemiology in the Department of social and preventive medicine at Laval University where he has been teaching since 1997. He is chief physician of the scientific immunization group (SIG) of the Institut national de santé publique du Québec and an active member of the Comité sur l’immunisation du Québec (CIQ).

Dr. De Serre works on the control and prevention of infectious diseases, with a focus on diseases that are avoidable through vaccination and on respiratory diseases. His research work is on the epidemiology of diseases that are preventable through vaccination and the efficacy of vaccinations used in routine programs, and in particular, on the efficacy of the influenza vaccine.

2400, avenue d'Estimauville, 3e étage
Québec, Québec
Canada G1E 7G9
+1 418-650-5115, extension 6274
+1 418-666-2776
gaston.de-serres@crchudeq... Gaston.DeSerres@inspq.qc....

Latest news

393 entries « ‹ 1 of 40 › »

Tauzin A, Benlarbi M, Medjahed H, Grégoire Y, Perreault J, Gendron-Lepage G, Gokool L, Morrisseau C, Arlotto P, Tremblay C, Kaufmann DE, Martel-Laferrière V, Levade I, Côté M, De Serres G, Bazin R, Finzi A

Humoral Responses against BQ.1.1 Elicited after Breakthrough Infection and SARS-CoV-2 mRNA Vaccination

Journal Article

Vaccines (Basel), 11 (2), 2023.

Abstract | Links:

Skowronski DM, Chuang ES, Sabaiduc S, Kaweski SE, Kim S, Dickinson JA, Olsha R, Gubbay JB, Zelyas N, Charest H, Bastien N, Jassem AN, De Serres G

Vaccine effectiveness estimates from an early-season influenza A(H3N2) epidemic, including unique genetic diversity with reassortment, Canada, 2022/23

Journal Article

Euro Surveill, 28 (5), 2023.

Abstract | Links:

Ionescu IG, Skowronski DM, Sauvageau C, Chuang E, Ouakki M, Kim S, De Serres G

BNT162b2 effectiveness against Delta and Omicron variants of SARS-CoV-2 in adolescents aged 12-17 years, by dosing interval and duration

Journal Article

J Infect Dis, 2023.

Abstract | Links:

Tauzin A, Nicolas A, Ding S, Benlarbi M, Medjahed H, Chatterjee D, Dionne K, Gong SY, Gendron-Lepage G, Bo Y, Perreault J, Goyette G, Gokool L, Arlotto P, Morrisseau C, Tremblay C, Martel-Laferrière V, De Serres G, Levade I, Kaufmann DE, Côté M, Bazin R, Finzi A

Spike recognition and neutralization of SARS-CoV-2 Omicron subvariants elicited after the third dose of mRNA vaccine

Journal Article

Cell Rep, 42 (1), 2023.

Abstract | Links:

Carazo S, Skowronski DM, Brisson M, Barkati S, Sauvageau C, Brousseau N, Gilca R, Fafard J, Talbot D, Ouakki M, Gilca V, Carignan A, Deceuninck G, De Wals P, De Serres G

Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study

Journal Article

Lancet Infect Dis, 23 (1), 2023.

Abstract | Links:

Nasreen S, Febriani Y, Velásquez García HA, Zhang G, Tadrous M, Buchan SA, Righolt CH, Mahmud SM, Janjua NZ, Krajden M, De Serres G, Kwong JC

Effectiveness of Coronavirus Disease 2019 Vaccines Against Hospitalization and Death in Canada: A Multiprovincial, Test-Negative Design Study

Journal Article

Clin Infect Dis, 76 (4), 2023.

Abstract | Links:

Bettinger JA, Irvine MA, Shulha HP, Valiquette L, Muller MP, Vanderkooi OG, Kellner JD, Top KA, Sadarangani M, McGeer A, Isenor JE, Marty K, Soe P, De Serres G,

Adverse Events Following Immunization with mRNA and Viral Vector Vaccines in Individuals with Previous SARS-CoV-2 Infection from the Canadian National Vaccine Safety Network

Journal Article

Clin Infect Dis, 2022.

Abstract | Links:

Nantel S, Bourdin B, Adams K, Carbonneau J, Rabezanahary H, Hamelin MÈ, McCormack D, Savard P, Longtin Y, Cheng MP, De Serres G, Corbeil J, Gilca V, Baz M, Boivin G, Quach C, Decaluwe H

Symptomatology during previous SARS-CoV-2 infection and serostatus before vaccination influence the immunogenicity of BNT162b2 COVID-19 mRNA vaccine

Journal Article

Front Immunol, 13 , 2022.

Abstract | Links:

Tauzin A, Gong SY, Chatterjee D, Ding S, Painter MM, Goel RR, Beaudoin-Bussières G, Marchitto L, Boutin M, Laumaea A, Okeny J, Gendron-Lepage G, Bourassa C, Medjahed H, Goyette G, Williams JC, Bo Y, Gokool L, Morrisseau C, Arlotto P, Bazin R, Fafard J, Tremblay C, Kaufmann DE, De Serres G, Richard J, Côté M, Duerr R, Martel-Laferrière V, Greenplate AR, Wherry EJ, Finzi A

A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses

Journal Article

Cell Rep, 41 (4), 2022.

Abstract | Links:

Carazo S, Skowronski DM, Brisson M, Sauvageau C, Brousseau N, Gilca R, Ouakki M, Barkati S, Fafard J, Talbot D, Gilca V, Deceuninck G, Garenc C, Carignan A, De Wals P, De Serres G

Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNA-Vaccinated and Nonvaccinated Individuals in Quebec, Canada

Journal Article

JAMA Netw Open, 5 (10), 2022.

Abstract | Links:

393 entries « ‹ 1 of 40 › »
Signaler des ajouts ou des modifications

Active projects

  • (SI03 QC03) Special Immunization Clinic Network (SIC) to investigate vaccine safety issues: Optimizing the clinical management of patients with contraindication to vaccination ..., from 2019-04-01 to 2023-03-31
  • Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) COVID-19 Vaccine Post-Market Studies, from 2020-12-01 to 2023-03-31
  • CV07 QC03 Canadian National Vaccine Safety (CANVAS) network: Surveillance of Adverse Events Following Immunization among children and adults Immunized with the COVID-19 Vaccine, from 2021-04-01 to 2023-03-31
  • SI05 QC03, Optimizing the clinical management of patients with adverse events following COVID-19 vaccination and potential contraindications to vaccination in the Special Immunization Clinic Network, from 2021-11-01 to 2023-03-31
  • SI06 QC03, Optimizing the clinical management of patients with adverse events following COVID-19 vaccination and potential contraindications to vaccination in the Special Immunization Clinic Network, from 2021-04-01 to 2023-03-31

Recently finished projects

  • (CV04 QC03) CANVAS Network - Surveillance of adverse events following immunization among children and adults immunized with the influenza vaccine, from 2017-06-01 to 2022-03-31
  • Canadian Immunization Research Network, from 2014-06-01 to 2021-12-31
  • COVID-19 household study to assess secondary attack rates and the proportion asymptomatic, including children, from 2020-06-01 to 2021-05-31
  • Efficacité des vaccins contre la CVOID-19, from 2021-04-20 to 2022-06-30
  • Identification de stratégies pour outiller les gestionnaires des milieux de soins pour l’application optimale des mesures de prévention et contrôle des infections chez les travailleurs de la santé durant la pandémie de COVID-19, from 2021-01-01 to 2022-02-08
  • Surveillance des hospitalisations et complications attribuables à l'influenza, saison 2018-2019 , from 2018-04-01 to 2021-03-31
  • Surveillance des manifestations cliniques survenant après la vaccination contre la COVID-19 au Québec, from 2020-12-01 to 2021-12-31
Data provided by the Université Laval research projects registery